Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[14C]Xeruborbactam Mass Balance Study
NCT07083817Phase 1Completed
- Sponsor
- Qpex Biopharma
- Start
- Aug 2025
- Primary completion
- Aug 2025
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of xeruborbactam in bacterial infection, sponsored by Qpex Biopharma. Primary endpoints: Amount of total radioactivity excreted expressed as a percentage of the radioactive dose administered (Fe), Cumulative amount of total radioactivity excreted expressed as percentage of the radioactive dose administered (CumFe) and 3 more. Started Aug 2025; status: completed.
02
Drugs
xeruborbactam
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT07083817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07083817.